Page 1

opSens PRESS RELEASE For Immediate Dissemination OPSENS ANNOUNCES FOURTH QUARTER AND FISCAL YEAR 2021 FINANCIAL RESULTS Conference call on the results today at 11 a.m. ET - Quebec City , Quebec , November 23 , 2021 OpSens Inc. ( " OpSens " or the " Company " ) ( TSX : OPS ) ( OTCQX : OPSSF ) , a medical device cardiology - focused company delivering innovative solutions based on its proprietary optical technology , today reported its results for the fourth quarter and fiscal year 2021 ended August 31 , 2021 . Fiscal Year Highlights • • • • Record total revenue of $ 34.5 million in FY 2021 compared with $ 29.5 million in FY 2020 , a 17 % increase ; Record sales of coronary artery disease products at $ 22.9 million in FY 2021 , compared with $ 18.7 million in FY 2020 , a 22 % increase ; Signed two agreements with major U.S. Group Purchasing Organizations ( GPO ) to provide its members with the Company's OptoWire ; OpSens Solutions received funding to develop an optical - based fuel monitoring system for aerospace applications , including civil aircrafts ; Awarded a contract to supply fiber optic absolute and differential pressure sensors for the International Thermonuclear Experimental Reactor ( ITER ) ; The Company closed a $ 28.75 million bought deal public offering in February 2021 ; Cash and cash equivalents at $ 38.6 million as of August 31 , 2021 , an increase of $ 27.7 million versus last year period ended August 31 , 2020 . Recent Highlights • OpSens successfully completed first in - man study with the SavvyWire , its new guidewire for transcatheter aortic valve replacement ( TAVR or TAVI ) procedures , can file product for regulatory 510 ( k ) clearance with the U.S. Food and Drug Administration ( " FDA " ) . Management Commentary " I am pleased with the strong progress made on both the operating and development sides of our business , as we report record annual revenues of $ 34.5 million in fiscal 2021 , while advancing our TAVR pipeline product with the completion of our in - man study . The many exciting developments of the past few months are setting OpSens up for continued growth , as we remain on track to commercialize our innovative product for TAVR in 2022 , " said Louis Laflamme , President and CEO of OpSens . " The closing of the $ 28.75 million financing in February will contribute to the enhancement of the commercialization and marketing strategy for TAVR and coronary artery disease products . " " The Company made great progress in the U.S. market , signing two , three - year contracts with major U.S. GPOs . An agreement signed with Cathmedical in Spain enables the integration of the OpSens system into the Picasso hemodynamic system and opens up additional seamless integrations like this in other markets , " Laflamme added . " We are optimistic as we look ahead to fiscal 2022 and beyond . Our continued progress over the past few years to create , manufacture and deliver innovative medical products was highlighted throughout the year . I congratulate the OpSens team for their determination to provide customers with continued access to our technology , " concluded Mr. Laflamme .